2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5018 Pre-clinical efficacy of the BD2-selective bromodomain and extra-terminal domain (BET) inhibitor VYN202 in models of advanced myeloproliferative neoplasm and post-MPN secondary AML cells

Warren Fiskus, PhD, Christopher P Mill, PhD2, Lucia Masarova, MD3, Hanxi Hou4, Caroline Hsu, N/A5, Naveen Pemmaraju, MD6, Iain Stuart, PhD7, Guillermo Garcia-Manero, MD8
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 VYNE Therapeutics, Stewartsville, New Jersey, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Stem/progenitor cells in advanced myeloproliferative neoplasms (MPNs) harbor disease-defining driver mutations in calreticulin (CALR), MPL, or JAK2, and exhibit constitutive activation of JAK-STAT5/3 and NF-κB signaling. These signaling pathways drive the aberrant biology and clinical manifestations of advanced MPNs, including grade ≥2 myelofibrosis (MF), extramedullary hematopoiesis, splenomegaly, and inflammatory cytokine-mediated constitutional symptoms. Treatment with JAK1/2 inhibitors such as ruxolitinib, provide meaningful clinical benefit by reducing splenomegaly and constitutional symptoms, but only modestly improve overall survival. Unfortunately,  acquisition of additional mutations in chromatin and transcriptional regulators including DNMT3A, TET2, ASXL1, EZH2, SRSF2, RUNX1, and TP53, promotes progression to MPN with excess blasts (MPN-EB; >5% blasts in bone marrow aspirate or peripheral blood), including accelerated phase (AP; 10–19% blasts) and secondary AML (sAML; ≥20% blasts). JAK inhibitor therapy does not prevent disease progression. Furthermore, in advanced MPN-EB/AP or post-MPN sAML, ruxolitinib, either alone or in combination with standard AML therapies, including hypomethylating agents and/or venetoclax, has not substantially improved clinical outcomes. Median survival for patients with MPN-EB/AP/sAML remains less than one year. Collectively, these findings highlight the critical unmet need for rationally designed targeted therapies and effective combination treatment strategies for patients with advanced MPN-EB/AP/sAML.

BRD4 is a member of the bromodomain extra-terminal (BET) family of chromatin reader proteins (BETP) that bind to acetylated lyine residues on histone proteins. BETPs regulate transcription through assembling a complex of co-regulatory proteins, including mediator protein and pTEFb (a heterodimer composed of CDK9 and its regulatory subunit Cyclin T), at regulatory elements including super enhancers, enhancers and promoters. BETP-CDK9 activity induces RNAP2-mediated mRNA transcript elongation at promoters of super enhancer/enhancer (SE/E)-driven oncogenes, including c-MYC, Bcl-xL, PIM1 and CDK4/6, which are important for cell growth and survival of AML, including post-MPN sAML cells.

Several small-molecule, acetyl-lysine-mimetic, pan-BET inhibitors (BETis) including pelabresib and birabresib have been developed and exhibit notable activity in vitro and in vivo growth and induce apoptosis of cultured and primary, patient-derived (PD) post-MPN sAML blasts. However, in clinical trials of the pan BD1 and BD2 BETi, thrombocytopenia and gastrointestinal toxicities were observed and dose limiting. VYN202 is an oral, potent small molecule and BD2-selective BET Inhibitor in clinical development. As BRD4 is a known dependency in hematologic malignancies, in the present studies, we determined the preclinical activity of VYN202 in post MPN sAML cells. Treatment with VYN202 induced in vitro loss of viability in post-MPN sAML SET2 and HEL cells, as well as in patient-derived (PD), CD34+ MPN-sAML but not in normal CD34+ progenitor cells. RNA-Seq analysis conducted after VYN202 treatment (1000 nM for 16 hours) showed significant negative-enrichment of the gene-sets of HALLMARK_MYC_TARGETS, HALLMARK_IL2_STAT5_SIGNALING, and IL6_JAK_STAT3_SIGNALING with log2 fold-decline in the mRNA levels of MYB, KIT, CDK6, FOSL1, PIM1, CD93 and CCND1, but upregulation of BCL2L11, CDKN1A, DCXR, and HEXIM1. Following VYN202 treatment of PD mutant CALR sAML cells, mass spectrometry demonstrated significant log2 fold-decline in c-Myc, c-Myb, CDK4, CDK6, PLK1, and FOSL1 but increases in p27, HEXIM1, BCL2L11 (BIM), HMOX1 and TGFB1 protein levels. Co-treatment with VYN202 and ruxolitinib or hypomethylating agent decitabine induced synergistic loss of viability in HEL, SET2 and PD MPN-sAML cells (delta synergy scores > 1.0 by the ZIP method). VYN202 treatment also exerted synergistic lethality with the CDK7 inhibitor SY5609 in MPN-sAML cells. In the SET2-Luc/GFP xenograft model in NSG mice, monotherapy with VYN202 (10 mg/kg/day, IP), vs vehicle, significantly reduced the MPN-sAML burden and improved survival, without causing any toxicity. These findings demonstrate promising preclinical activity of VYN202 against the cellular models of MPN-sAML, supporting the rationale to further evaluate in vivo efficacy of VYN202-based combinations against advanced MPN with excess blasts or post-MPN sAML.

Warren Fiskus, PhD: No relevant conflicts of interest to declare.